Page number 31
16 Investor presentation First nine months of 2024 R&D milestones Project Q3 2024 Diabetes care FLOW (CKD, Sema 1.0 mg) ✓ CN submissio IcoSema STRIDE (PAD, Sema 1.0 mg) ✓ Phase 3 resul SOUL (CVOT, Oral sema 14 mg) Monlunabant (INV-202) (DKD) Amycretin ✓ Phase 2 initiati Obesity care STEP HFpEF (Sema 2.4 mg) ✓ EU positive opin STEP 9 (OA) (Sema 2.4 mg) STEP UP (Sema 7.2 mg) CagriSema Monlunabant (INV-202) ✓ Phase 2 resul Amycretin s.c. Amylin 355 ✓ Phase 1 initiati Rare Disease Mim8 Etavopivat SCD ✓ Phase 2 results (in Inno8 ✓ Phase 1 initiati CETA ESSENCE (MASH, Sema 2.4 mg) 1 Expected to be published in the given quarter or in the subsequent quarterly company announcement CETA: Cardiovascular & emerging therapies; CKD: Chronic Kidney Disease; CN: China; CV: Cardiovascular; CVOT: Cardiovascular out Metabolic dysfunction-associated steatohepatitis; PAD: Peripheral arterial disease; Sema: Semaglutide; SCD: Sickle cell disease; T2D
Page number 32
Novo Nordisk ® Clinical milestones 1 Regulatory milestones 1 on lts ion nion lts ion nterim) ion Q4 2024 EU ( ✓ ) / CN submission ✓ Phase 3 results Phase 2 results ✓ EU positive opinion Phase 3 results Phase 3 results (REDEFINE 1) ✓ Phase 3 results (FRONTIER 5) H1 2025 EU/US decision JP submission US/EU/CN/JP submission US/EU submission US resubmission Phase 3 results (REDEFINE 2) Phase 1 results ✓ Phase 3 results US/EU submission tcomes trial; DKD: Diabetic kidney disease; EU: European Union; HFpEF: Heart failure with preserved ejection fraction; MASH: D: Type 2 Diabetes; US: United States
